Skip to main content

Advertisement

Table 3 Clinical characteristics in the two subgroups of prefibrotic and fibrotic PMF

From: Thrombosis in essential thrombocytemia and early/prefibrotic primary myelofibrosis: the role of the WHO histological diagnosis

  Prefibrotic PMF Fibrotic PMF p value
Sex M:F = 11/15 M:F = 15/31 n.s.
Median age at diagnosis (years) 43 (20–87) 61 (27–83) p = 0.019
WBC at diagnosis (109/l) 9100 8745 n.s.
Hb at diagnosis (g/dl) 14.6 14.3 n.s.
PLT at diagnosis (109/l) 825000 797500 n.s.
Increased LDH 6/19 (31.6%) 19/31 (61.3%) n.s.
Splenomegaly (%) 6 (23%) 12 (26%) n.s.
JAK2V617-positive (%) 9 (50%) 14 (58%) n.s.
History of thrombosis (%) 6 (23%) 10 (22%) n.s.
Thrombosis at diagnosis (%) 4 (15%) 7 (15%) n.s.
Thrombotic events during follow-up (%) 6 (23%) 5 (10%) n.s.
Progression to overt MF (%) 0 (0%) 3 (6.5%) n.s.
Dead/Alive 2/24 6/40 n.s.
Conventional Risk (Low/High) 13/13 17/29 n.s.
Cytoreductive therapy (%) 24 (92%) 40 (86%) n.s.